In recent studies, in addition to tumor stage, grading and hormone-receptor status, a variety of additional markers have been evaluated, including the 21-gene recurrence score, the PAM50 risk of recurrence score and changes in Ki-67 after short-term endocrine therapy [10, 24, 25, 29, 30]. Here, NR4A1 is linked to neoplasm.